Cost-effectiveness of esketamine nasal spray compared to intravenous ketamine for patients with treatment-resistant depression in the US utilizing clinical trial efficacy …
Objective The aim of this study was to estimate the cost-effectiveness of esketamine nasal
spray relative to intravenous ketamine for patients with treatment-resistant depression (TRD) …
spray relative to intravenous ketamine for patients with treatment-resistant depression (TRD) …
Cost-effectiveness of esketamine nasal spray for patients with treatment-resistant depression in the United States
EL Ross, DI Soeteman - Psychiatric Services, 2020 - Am Psychiatric Assoc
Objective: This study aimed to estimate the cost-effectiveness of esketamine, a novel
intranasally dosed antidepressant, for patients in the United States with treatment-resistant …
intranasally dosed antidepressant, for patients in the United States with treatment-resistant …
Treatment patterns, healthcare utilization, and costs of patients with treatment-resistant depression initiated on esketamine intranasal spray and covered by US …
Aims To describe real-world use of esketamine (ESK) intranasal spray and healthcare
outcomes among patients with treatment-resistant depression (TRD) in the United States …
outcomes among patients with treatment-resistant depression (TRD) in the United States …
Appraising esketamine nasal spray for the management of treatment-resistant depression in adults: number needed to treat, number needed to harm, and likelihood to …
Introduction This post hoc study assessed the evidence-base for esketamine nasal spray for
management of treatment-resistant depression (TRD) using number needed to treat (NNT) …
management of treatment-resistant depression (TRD) using number needed to treat (NNT) …
ICEBERG study: an indirect adjusted comparison estimating the long-term benefit of esketamine nasal spray when compared with routine treatment of treatment …
AJ Oliveira-Maia, J Morrens, B Rive, Y Godinov… - Frontiers in …, 2023 - frontiersin.org
Background Treatment resistant depression (TRD) affects 10–30% of patients with major
depressive disorder. In 4-week trials, esketamine nasal spray (NS) was efficacious vs …
depressive disorder. In 4-week trials, esketamine nasal spray (NS) was efficacious vs …
[HTML][HTML] Characteristics of real-world commercially insured patients with treatment-resistant depression initiated on esketamine nasal spray or conventional therapies …
Purpose This study aimed to characterize patients with treatment-resistant depression (TRD)
initiating esketamine or conventional therapies. Methods Adults with major depressive …
initiating esketamine or conventional therapies. Methods Adults with major depressive …
Indirect adjusted comparison of 6-month clinical outcomes between esketamine nasal spray and other real-world polypharmacy treatment strategies for treatment …
AJ Oliveira-Maia, B Rive, J Morrens, Y Godinov… - Frontiers in …, 2023 - frontiersin.org
Background The efficacy of esketamine nasal spray (NS) as a rapid-acting agent for
treatment resistant depression (TRD) was demonstrated in comparisons with placebo, when …
treatment resistant depression (TRD) was demonstrated in comparisons with placebo, when …
Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression
U Desai, NY Kirson, A Guglielmo… - Journal of …, 2021 - becarispublishing.com
Aim: Estimate the cost-per-remitter with esketamine nasal spray plus an oral antidepressant
(ESK+ oral AD) versus oral AD plus nasal placebo (oral AD+ PBO) among patients with …
(ESK+ oral AD) versus oral AD plus nasal placebo (oral AD+ PBO) among patients with …
Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance
A Teeple, M Zhdanava, D Pilon… - Current Medical …, 2023 - Taylor & Francis
Objective To describe access and real-world use patterns of esketamine nasal spray among
adults with treatment-resistant depression (TRD) with private or public insurance. Methods …
adults with treatment-resistant depression (TRD) with private or public insurance. Methods …
Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double …
M Fedgchin, M Trivedi, EJ Daly… - International Journal …, 2019 - academic.oup.com
Background About one-third of patients with depression fail to achieve remission despite
treatment with multiple antidepressants and are considered to have treatment-resistant …
treatment with multiple antidepressants and are considered to have treatment-resistant …